Mark W. Hahn
2022 - Verona Pharma plc
In 2022, Mark W. Hahn earned a total compensation of $4.8M as Chief Financial Officer at Verona Pharma plc, a 546% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $331,531 |
|---|---|
| Salary | $430,450 |
| Stock Awards | $3,983,498 |
| Other | $22,401 |
| Total | $4,767,880 |
Hahn received $4M in stock awards, accounting for 84% of the total pay in 2022.
Hahn also received $331.5K in non-equity incentive plan, $430.5K in salary and $22.4K in other compensation.
Rankings
In 2022, Mark W. Hahn's compensation ranked 680th out of 5,756 executives tracked by ExecPay. In other words, Hahn earned more than 88.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 680 out of 5,756 | 88th |
Division Manufacturing | 296 out of 3,133 | 91st |
Major group Chemicals And Allied Products | 91 out of 1,419 | 94th |
Industry group Drugs | 78 out of 1,320 | 94th |
Industry Pharmaceutical Preparations | 57 out of 966 | 94th |
Source: SEC filing on March 21, 2023.
Hahn's colleagues
We found two more compensation records of executives who worked with Mark W. Hahn at Verona Pharma plc in 2022.